Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review von Li, Claire H, Karantza, Vassiliki, Aktan, Gursel, Lala, Mallika

Volltext

Clarification on Precision Criteria to Derive Sample Size When Designing Pediatric Pharmacokinetic Studies von Wang, Yaning, Jadhav, Pravin R., Lala, Mallika, Gobburu, Jogarao V.

Volltext

Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study von Cohen, Graham, Rapoport, Bernardo, Chan, Sze W, Ruff, Paul, Arance, Ana, Mujika Eizmendi, Karmele, Houghton, Baerin, Brown, Michael P, Zielinski, Robert M, Muñoz Couselo, Eva, Lyle, Megan, Anderson, James R, Jain, Lokesh, de Alwis, Dinesh, Lala, Mallika, Akala, Omobolaji, Chartash, Elliot, Jacobs, Conrad

Volltext

Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections von Bhagunde, Pratik, Patel, Parul, Lala, Mallika, Watson, Kenny, Copalu, William, Xu, Ming, Kulkarni, Pooja, Young, Katherine, Rizk, Matthew L.

Volltext

Immunogenicity of pembrolizumab in patients with advanced tumors von van Vugt, Marianne J H, Stone, Julie A, De Greef, Rik H J M M, Snyder, Ellen S, Lipka, Leslie, Turner, David C, Chain, Anne, Lala, Mallika, Li, Mengyao, Robey, Seth H, Kondic, Anna G, De Alwis, Dinesh, Mayawala, Kapil, Jain, Lokesh, Freshwater, Tomoko

Volltext

Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review von Lala, Mallika, Chirovsky, Diana, Cheng, Jonathan D., Mayawala, Kapil

Volltext

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation von Lala, Mallika, Li, Tommy Ruosi, de Alwis, Dinesh P., Sinha, Vikram, Mayawala, Kapil, Yamamoto, Noboru, Siu, Lillian L., Chartash, Elliot, Aboshady, Hesham, Jain, Lokesh

Volltext

Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection von Lucasti, Christopher, Vasile, Liviu, Sandesc, Dorel, Venskutonis, Donatas, McLeroth, Patrick, Lala, Mallika, Rizk, Matthew L, Brown, Michelle L, Losada, Maria C, Pedley, Alison, Kartsonis, Nicholas A, Paschke, Amanda

Volltext

Pivotal Dose of Pembrolizumab: A Dose‐Finding Strategy for Immuno‐Oncology von Li, Tommy R., Chatterjee, Manash, Lala, Mallika, Abraham, Anson K., Freshwater, Tomoko, Jain, Lokesh, Sinha, Vikram, Alwis, Dinesh P., Mayawala, Kapil

Volltext

Abstract CT042: Pembrolizumab 400 mg Q6W dosing: First clinical outcomes data from Keynote-555 cohort B in metastatic melanoma patients von Lala, Mallika, Akala, Omobolaji, Chartash, Elliot, Kalabis, Mizuho, Su, Shu-Chih, de Alwis, Dinesh, Sinha, Vikram, Jain, Lokesh

Volltext

Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma von Cohen, Graham, Rapoport, Bernardo, Chan, Sze W, Ruff, Paul, Arance, Ana, Mujika Eizmendi, Karmele, Houghton, Baerin, Brown, Michael P, Zielinski, Robert M, Muñoz Couselo, Eva, Lyle, Megan, Anderson, James R, Jain, Lokesh, de Alwis, Dinesh, Lala, Mallika, Akala, Omobolaji, Chartash, Elliot, Jacobs, Conrad

Volltext

Simplification of Imipenem Dosing by Removal of Weight‐Based Adjustments von Lala, Mallika, Brown, Michelle, Kantesaria, Bhavna, Walker, Brittany, Paschke, Amanda, Rizk, Matthew L.

Volltext

A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation von Lala, Mallika, Li, Mengyao, Sinha, Vikram, de Alwis, Dinesh, Chartash, Elliot, Jain, Lokesh

Volltext

Abstract CT143: Pembrolizumab bioavailability after subcutaneous administration: analysis from the KEYNOTE-555 Cohort A in metastatic melanoma von Jacobs, Conrad R., Rapoport, Bernardo Leon, Cohen, Graham Lawrence, Lala, Mallika, Silva, Carolina De Miranda, Vaddady, Pavan, Gheyas, Ferdous, de Alwis, Dinesh, Sinha, Vikram, Akala, Omobolaji Oyekunle, Chartash, Elliot, Jain, Lokesh

Volltext

KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab (pembro) 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma von Jacobs, Conrad R., Rapoport, Bernardo Leon, Chan, Sze Wai, Ruff, Paul, Arance, Ana Maria, Mujika, Karmele, Anderson, James Robert, Lala, Mallika, Jain, Lokesh, Akala, Omobolaji Oyekunle, Chartash, Elliot, Cohen, Graham Lawrence

Volltext

Corrigendum to “A six-weekly (Q6W) dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation” [Eur J Canc 131 (2020) 68–75] von Lala, Mallika, Li, Tommy Ruosi, de Alwis, Dinesh P., Sinha, Vikram, Mayawala, Kapil, Li, Mengyao, Yamamoto, Noboru, Siu, Lillian L., Chartash, Elliot, Aboshady, Hesham, Jain, Lokesh

Volltext

Genetics-based pediatric warfarin dosage regimen derived using pharmacometric bridging von Lala, Mallika, Burckart, Gilbert J, Takao, Cheryl M, Pravica, Vera, Momper, Jeremiah D, Gobburu, Jogarao V S

Volltext

Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin von Bhagunde, Pratik, Colon‐Gonzalez, Francheska, Liu, Yang, Wu, Jin, Xu, Shiyao Sherrie, Garrett, Graigory, Jumes, Patricia, Lasseter, Kenneth, Marbury, Thomas, Rizk, Matthew L., Lala, Mallika, Rhee, Elizabeth G., Butterton, Joan R., Boundy, Keith

Volltext

Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid von Hasselt, J. G. Coen, Rizk, Matthew L., Lala, Mallika, Chavez‐Eng, Cynthia, Visser, Sandra A. G., Kerbusch, Thomas, Danhof, Meindert, Rao, Gauri, Graaf, Piet H.

Volltext

Abstract CT180: Safety and efficacy of vibostolimab (vibo) plus pembrolizumab (pembro) and coformulation of vibo/pembro in ovarian cancer naive to PD-1/PD-L1 inhibitors von Perets, Ruth, Gutierrez, Martin, Rha, Sun Young, Taylor, Sarah, Stein, Brian, Jimeno, Antonio, Winer, Ira, Chen, Diana, Keenan, Tanya, Rajasagi, Mohini, Lala, Mallika, Healy, Jane, Shapira-Frommer, Ronnie

Volltext